NASDAQ · STAA
Healthcare · Medical - Instruments & Supplies
$25.24
Down-$0.17 (-0.68%)
Updated Oct 30, 2026, 1:46 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · STAA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
STAA closed at $25.24 after 21 trading sessions, up 12.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $24.78 | $25.52 | $24.61 | $25.24 | 454.62K |
| Oct 28, 2026 | $24.03 | $24.99 | $23.94 | $24.61 | 675.36K |
| Oct 27, 2026 | $23.23 | $24.25 | $23.02 | $24.16 | 605K |
| Oct 26, 2026 | $22.58 | $23.59 | $22.1123 | $23.23 | 748.91K |
| Oct 23, 2026 | $22.47 | $22.67 | $22.29 | $22.61 | 345.23K |
| Oct 22, 2026 | $21.61 | $22.68 | $21.61 | $22.49 | 416.25K |
| Oct 21, 2026 | $22.04 | $22.31 | $21.50 | $21.61 | 338.49K |
| Oct 20, 2026 | $21.90 | $22.569 | $21.85 | $22.32 | 614.6K |
| Oct 19, 2026 | $21.15 | $21.95 | $21.15 | $21.88 | 680.35K |
| Oct 16, 2026 | $22.23 | $22.23 | $21.06 | $21.27 | 636.69K |
| Oct 15, 2026 | $22.03 | $22.435 | $21.95 | $22.26 | 626.11K |
| Oct 14, 2026 | $21.35 | $21.89 | $21.225 | $21.84 | 552.89K |
| Oct 13, 2026 | $21.83 | $22.16 | $21.24 | $21.50 | 446.91K |
| Oct 12, 2026 | $21.67 | $22.10 | $21.30 | $22.01 | 596.01K |
| Oct 9, 2026 | $22.29 | $22.52 | $21.445 | $21.67 | 592.5K |
| Oct 8, 2026 | $22.33 | $22.64 | $22.06 | $22.38 | 639.65K |
| Oct 7, 2026 | $22.08 | $22.705 | $21.96 | $22.36 | 779.78K |
| Oct 6, 2026 | $22.57 | $22.665 | $21.89 | $22.15 | 637.47K |
| Oct 5, 2026 | $22.31 | $22.60 | $21.93 | $22.57 | 471.89K |
| Oct 2, 2026 | $22.43 | $22.78 | $22.085 | $22.47 | 640.04K |
| Oct 1, 2026 | $22.63 | $22.97 | $22.01 | $22.38 | 776.26K |
The latest Smart Investors Daily articles mentioning STAA.
Company
Market Activity
Research & News
STAA research
Company profile and research snapshot.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Stifel | Buy | — |
| Sep 22, 2026 | Jefferies | Buy | — |
| Aug 17, 2026 | Stifel | Hold | — |
| Aug 13, 2026 | UBS | Sell | — |
| Aug 13, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 27, 2026
LAKE FOREST, Calif., October 27, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Warren Foust, President and Chief Executive Officer, and Deborah Andrews, Executive Vice President and Chief Financial Officer, will participate in two investor conferences in November:
Yahoo · Oct 21, 2026
LAKE FOREST, Calif., October 21, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday, November 4, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET that same day to discuss its financial results
Yahoo · Oct 14, 2026
Earlier in 2026, STAAR Surgical created a new vice president of business development role and appointed Andrew Pilon, OD, a veteran of Johnson & Johnson Vision with extensive ophthalmology and deal-making experience, to help advance its innovation strategy and expand its implantable lens portfolio. This move comes as the company faces flat revenue trends and weaker return on invested capital, highlighting management’s focus on sourcing new growth avenues and improving how capital is...
Yahoo · Oct 13, 2026
STAAR Surgical has seen its share price fall sharply over the past few years, even as recent headlines highlight strong revenue growth and new leadership hires. That mix of weak long term returns and upbeat news leaves a clear question for investors who follow STAAR Surgical: whether the current US$22.01 share price lines up with what its cash flows can support. Over the past 5 years the stock has fallen 81.3%, which puts the focus squarely on whether the underlying cash flow potential...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STAA.
